Fed. Circ. Revives Santarus' Suit Over Par's Generic Zegerid

Law360, New York (September 4, 2012, 10:33 PM EDT) -- The Federal Circuit on Tuesday partially revived Santarus Inc.'s bid to block Par Pharmaceutical Co.’s generic version of the heartburn drug Zegerid, reversing a lower court's ruling that claims of two patents governing the drugs' absorption were invalidated by obviousness.

In a per curiam, precedential opinion, a three-judge panel said that a Delaware federal judge erred in invalidating as obvious two Santarus patents that allow Zegerid to be more easily administered.

"We reverse this portion of the district court judgment and hold that Par did not...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.